GET DAILY SIGNALSP3 Health Partners (PIII) Delivers Turnaround with Q3 Profit and Raised Guidance
Key Takeaways
- P3 Health Partners reported third quarter 2026 total revenue of $396.3 million, up 15% year over year, beating the consensus estimate of roughly $385 million.
- The company swung to net income of $30.8 million, compared with a net loss of $69.5 million in the prior-year quarter.
- Diluted earnings per share (EPS) reached $0.07, a sharp improvement from a loss of $9.67 per share a year earlier.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $20.9 million, versus a $45.9 million loss a year ago, and management raised the midpoint of its full-year 2026 Adjusted EBITDA guidance to $100 million.
- At-risk membership declined 9% year over year to approximately 105,000 members, reflecting the company's deliberate network and payer rationalization strategy.
Why This Quarter Matters
P3 Health Partners is a patient-centered, physician-led population health management company that supports primary care providers with value-based care coordination and administrative services. After years of losses, the company has been executing a deliberate turnaround centered on rationalizing its provider network and improving the economics of its capitated Medicare Advantage contracts. This quarter matters because it offers the clearest sign yet that the turnaround is translating into sustained profitability. With Adjusted EBITDA turning positive for a third consecutive quarter and management lifting its full-year guidance midpoint, investors are watching closely to see whether PIII can carry its improved medical cost trends and operating discipline into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
For the third quarter ended September 30, 2026, P3 Health Partners reported total operating revenue of $396.3 million, an increase of 15% compared with $345.3 million in the prior-year quarter and above the consensus estimate of about $385 million. Capitated revenue rose to $366.3 million, while other revenue climbed to $30.1 million from $3.7 million a year earlier.
The company posted net income of $30.8 million, a dramatic reversal from the $69.5 million net loss reported in the same period last year. Diluted EPS came in at $0.07, compared with a loss of $9.67 per share a year ago. Net income attributable to Class A common stockholders was $451,000, or $0.13 basic EPS, after cumulative preferred stock dividends of $15.2 million.
On an operating basis, Adjusted EBITDA reached $20.9 million, or $66 per member per month (PMPM), versus a loss of $45.9 million a year earlier. Medical margin for the quarter was $43.9 million, or $140 PMPM, though this figure benefited from favorable payer settlements and prior-year development. Excluding those items, medical margin was $35.0 million, or $111 PMPM. At-risk membership was approximately 105,000, down 9% year over year, while total lives under management stood at roughly 133,500.
Management revised its full-year 2026 Adjusted EBITDA guidance to a range of $90 million to $110 million, raising the midpoint to $100 million. Full-year revenue guidance was maintained at $1.525 billion to $1.600 billion.
Market Reaction and Investor Sentiment
Shares of PIII moved higher following the release, as investors responded to the company's larger-than-expected profit swing and the upward revision to its Adjusted EBITDA guidance. The market's initial read focused on the durability of the earnings improvement, with management emphasizing year-to-date Adjusted EBITDA of $101 million and a normalized Medicare Advantage medical expense trend that remains below prior-year levels.
At the same time, sentiment was tempered by signs that the quarter's headline results carried meaningful one-time support. Roughly $12 million of the $21 million in Adjusted EBITDA came from items such as a favorable 2025 CMS ACO reconciliation and a non-cash liability release, while the adjusted medical loss ratio rose sequentially to about 90.6%. Investors are weighing the strength of the underlying business against these non-recurring contributions.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be focused on whether P3 Health Partners can sustain its profitability into 2027. Management has identified more than $200 million of potential multi-year value creation across payer economics, clinical execution, and operating efficiency, and has said it will provide greater clarity on the timing and earnings contribution of these opportunities early in 2027.
The trajectory of medical costs will be a central watch item. Although Medicare Advantage medical expense remains favorable versus prior-year levels on a normalized basis, the third quarter showed a sequential uptick in the medical loss ratio, driven in part by outpatient and professional services utilization. Sustaining cost discipline will be essential to protecting margins. From what I see, this remains a key area to track closely.
Other factors to monitor include the ramp of the Nebraska build-out, progress in growing per-member capitated revenue, and the company's pipeline of Medicare Advantage plan opportunities. Membership trends will also matter: the intentional reduction in at-risk lives has improved economics, but investors will want to see the base stabilize and begin to grow again. The recent appointment of a new Chief Clinical Officer adds another layer to watch as P3 deepens its clinical execution ahead of 2027 guidance.
Using AI Tools in My Research Process
In reviewing names like PIII, I often turn to Tickeron’s AI Screener to scan for comparable opportunities and technical signals. It helps me filter the market efficiently and surface ideas that align with my focus on value-based care names, complementing the fundamental review of earnings reports like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PIII sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for PIII moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PIII declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PIII entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PIII's RSI Oscillator exited the oversold zone, 34 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on PIII as a result. In 68 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for PIII just turned positive on October 22, 2026. Looking at past instances where PIII's MACD turned positive, the stock continued to rise in 29 of 35 cases over the following month. The odds of a continued upward trend are 83%.
Following a +11.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where PIII advanced for three days, in 197 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PIII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.170) is normal, around the industry mean (204.532). P/E Ratio (-0.121) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.017) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. PIII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PIII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement